DGAP-News

STRATEC reports substantial growth in 2016

DGAP-News: STRATEC Biomedical AG / Key word(s): Final Results STRATEC reports substantial growth in 2016 20.04.2017 / 07:34 The issuer is solely responsible for the content of this announcement. STRATEC reports substantial growth in 2016

- Sales of EUR 184.9 million (+25.9%; previous year: EUR 146.9 million)

- EBITDA of EUR 38.7 million¹ (+13.1 %; previous year: EUR 34.2 million)

- EBIT of EUR 32.3 million¹ (+20.1%; previous year: EUR 26.9 million)

- EBIT margin of 17.5%¹ (-80 basis points; previous year: 18.3%)

- Consolidated net income of EUR 25.4 million² (+14.9%; previous year: EUR 22.1 million)

- Earnings per share of EUR 2.14² (+14.4%; previous year: EUR 1.87)

- Dividend proposal of EUR 0.77 per share (dividend in previous year: EUR 0.75 per share)

Birkenfeld, April 20, 2017

STRATEC Biomedical AG, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard) announced today the definitive results of the STRATEC Group for the financial year as of December 31, 2016 with the publication of its 2016 Annual Report. These figures, prepared in line with International Financial Reporting Standards (IFRS), have been audited and granted an unqualified audit opinion.

Key figures (EUR 000s)	2016	2015	Change
Sales	184,911	146,886	+25.9%
Adjusted EBITDA	38,677	34,207	+13.1%
Adjusted EBITDA margin (%)	20.9	23.3	-240 bps
EBIT	32,2731	26,875	+20.1%
EBIT margin (%)	17.51	18.3	-80 bps
Consolidated net income	25,3832	22,084	+14.9%
Earnings per share (EUR)	2.142	1.87	+14.4%